The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.
Status:
Completed
Trial end date:
1999-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and efficacy of the buprenorphine
transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and
hydrocodone/acetaminophen in subjects with chronic back pain. The double-blind treatment
intervention duration is 56 days during which time supplemental analgesic medication
(ibuprofen) will be provided to all subjects in addition to study drug.